2,443 results match your criteria Advances in therapy[Journal]


Mental Health Status in Patients Undergoing Intracoronary Acetylcholine Provocation Test.

Adv Ther 2020 Jul 10. Epub 2020 Jul 10.

Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Background: Previous studies showed the relation of mental distress such as anxiety and depression to coronary vasoconstriction and myocardial ischemia. However, the mental health status of patients suspected to have vasospastic angina is unclear.

Methods: A total of 99 patients underwent intracoronary acetylcholine (ACh) provocation tests for the diagnosis of vasospastic angina and mental health assessment using the 12-item General Health Questionnaire (GHQ-12) and State-Trait Anxiety Inventory Form Y (STAI Y-2). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01424-9DOI Listing

Letter to the Editor Regarding Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review.

Adv Ther 2020 Jul 9. Epub 2020 Jul 9.

GOED (Global Organization for EPA and DHA Omega-3s), Salt Lake City, UT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01421-yDOI Listing

Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.

Adv Ther 2020 Jul 9. Epub 2020 Jul 9.

School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People's Republic of China.

Introduction: This study aimed to evaluate the cost-effectiveness of cisplatin plus gemcitabine vs. paclitaxel plus gemcitabine as a first-line treatment for metastatic triple-negative breast cancer in China.

Methods: The Markov model and partitioned survival (PS) model were used, and the study included three health states over the period of a lifetime. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01418-7DOI Listing

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study.

Adv Ther 2020 Jul 9. Epub 2020 Jul 9.

GlaxoSmithKline plc, Collegeville, PA, USA.

Introduction: The phase 3 InforMing the PAthway of COPD (chronic obstructive pulmonary disease) Treatment (IMPACT) trial, single-inhaler therapy with fluticasone furoate (FF) 100 μg, umeclidinium (UMEC) 62.5 μg, and vilanterol (VI) 25 μg demonstrated a reduction in the rate of moderate or severe exacerbations compared with FF/VI or UMEC/VI in patients with symptomatic COPD at risk of exacerbations. This article reports additional evidence of improvements in symptoms and health-related quality of life (HRQoL) with FF/UMEC/VI compared with either FF/VI or UMEC/VI from the IMPACT study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01409-8DOI Listing

Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study.

Adv Ther 2020 Jul 9. Epub 2020 Jul 9.

Center for Observational and Real-World Evidence, Merck & Co., Inc, Kenilworth, NJ, USA.

Introduction: Subsequent lines of subcutaneous tumor necrosis factor alpha inhibitor (SC-TNFi) treatment may be well motivated in the management of rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA)-collectively named inflammatory arthritis (IA). However, the costs associated with switching SC-TNFis are largely unknown. The objective of this retrospective observational study was to explore costs of healthcare resource utilization (HCRU) associated with switching SC-TNFi treatment among biologic-naïve Swedish patients with IA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01425-8DOI Listing

Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis.

Adv Ther 2020 Jul 9. Epub 2020 Jul 9.

Global Evidence and Value Development, Global Research and Development, EMD Serono, Inc, Billerica, MA, USA.

Introduction: To develop a simulation model assessing the efficiency of using cladribine tablets versus infusion-based disease-modifying drugs (DMDs) for the treatment of relapsing-remitting multiple sclerosis (RRMS) from a facility perspective in the UK.

Methods: A scheduling algorithm was developed to simulate day-case admissions and calculate the mean changes to resource use and time burden for patients in a facility that transitions from infusion-based treatments to cladribine tablets over 1 year. Model inputs and assumptions were based on previous research and expert opinion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01426-7DOI Listing

Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors.

Adv Ther 2020 Jul 8. Epub 2020 Jul 8.

Duke University Medical Center, Durham, NC, USA.

Introduction: Chemotherapy-induced myelosuppression (CIM) is one of the most common dose-limiting complications of cancer treatment, and is associated with a range of debilitating symptoms that can significantly impact patients' quality of life. The purpose of this study was to understand patients' perspectives on how the side effects of CIM are managed in routine clinical practice.

Methods: An online survey was conducted of participants with breast, lung, or colorectal cancer who had received chemotherapy treatment within the past 12 months, and had experienced at least one episode of myelosuppression in the past year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01419-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340862PMC

Patients with BRAF-Mutant Advanced/Metastatic Melanoma: Original Research on the Treatment Reality in Germany and Austria in the Era of Choice.

Adv Ther 2020 Jul 8. Epub 2020 Jul 8.

LKH-Universitätsklinikum Graz, Klinik für Dermatologie und Venerologie, Graz, Austria.

Introduction: Cutaneous melanoma is one of the most aggressive forms of skin neoplasms and represents a major cause of neoplastic or cancer death in Europe. Without adequate therapy, the 5-year survival rate is 15% when the disease metastasizes to distant organs. The objective of our study was to evaluate the status quo of the current treatment standards in stage IV melanoma and rationale for therapy decisions in Germany and Austria between January 2016 and September 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01430-xDOI Listing

Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.

Adv Ther 2020 Jul 7. Epub 2020 Jul 7.

Astellas Pharma Global Development, Inc., Northbrook, IL, USA.

Introduction: Although antimuscarinics form the first-line therapy in overactive bladder (OAB), little is known regarding antimuscarinic discontinuation among OAB patients in nursing homes. This study examined treatment patterns and predictors of antimuscarinic discontinuation among long-term nursing home (LTNH) residents with OAB.

Methods: The study cohort included LTNH residents (defined as residents staying ≥ 101 consecutive days) from the Minimum Data Set linked 2013-2015 Medicare claims data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01412-zDOI Listing

Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature.

Adv Ther 2020 Jul 6. Epub 2020 Jul 6.

Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran.

The COVID-19 outbreak was declared a pandemic on March 2020. Many patients with SARS-CoV-2 infection have underlying chronic medical conditions such as diabetes, cardiovascular disease (CVD), and hypertension. Patient-related outcomes are worse if there are associated comorbidities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01417-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338141PMC

Cannabis Use in Hospitalized Patients with Chronic Pain.

Adv Ther 2020 Jul 6. Epub 2020 Jul 6.

Department of Anesthesiology, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Introduction: To date, no study has reported the prevalence of cannabis use in chronic pain patients. The aim of this study is to investigate the trends in cannabis use among chronic pain in-patients from 2011 to 2015 in the USA.

Methods: Patients were identified from the National Inpatient Sample (NIS) database using the International Classification of Diseases, Ninth and Tenth Revision, diagnosis codes for chronic pain and cannabis use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01416-9DOI Listing

Primary Care Physicians' Knowledge of the Cardiovascular Effects of Diabetes Medications: Findings from an Online Survey.

Adv Ther 2020 Jul 4. Epub 2020 Jul 4.

University of California, San Diego, CA, USA.

Introduction: Cardiovascular (CV) outcomes trial (CVOT) results have led to changes in indications for some glucose-lowering agents, with recommendations based on the presence of comorbidities.

Objective: This study aimed to understand internal medicine (IM) and family medicine (FM) physicians' knowledge of CVOTs and beliefs about type 2 diabetes mellitus (T2DM) medications, excluding insulin, for CV disease risk reduction.

Methods: WebMD, LLC, fielded a 23-item online survey from September 18 to 20, 2018, to 47,534 Medscape members (US IM and FM physicians) who were invited to participate via e-mail (quota = 500). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01405-yDOI Listing

Low Level Laser Therapy in Knee Osteoarthritis: A Narrative Review.

Adv Ther 2020 Jul 3. Epub 2020 Jul 3.

Musculoskeletal Research Center, Rehabilitation Sciences Research Institute, Department of Physical Therapy, Faculty of Rehabilitation Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.

Knee osteoarthritis (KOA) is the most common musculoskeletal disorder, especially in middle up to old age. KOA also results in many complications like changes in gait. Nowadays, changes in lifestyle and the reduced physical activity make people more vulnerable to KOA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01415-wDOI Listing

Profile of Cardiovascular Disease Patients Who are Diagnosed with COPD in a Smoking-Cessation Unit.

Adv Ther 2020 Jun 13. Epub 2020 Jun 13.

Medical Department Rovi Labs, Madrid, Spain.

Introduction: Cardiovascular diseases (CVDs) and chronic obstructive pulmonary disease (COPD) have similar prevalence rates and risk factors, and both frequently occur in the same patient. The primary objective of the study was to evaluate the rate of COPD patients among subjects with some form of CVD referring to a smoking cessation unit. The secondary objective was to analyze the demographic and clinical profile of these subjects and to identify independent factors potentially associated with COPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01403-0DOI Listing

Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A Single-Center, Open-Label, Randomized Controlled Trial.

Adv Ther 2020 Jun 24. Epub 2020 Jun 24.

Department of Hypertension and Vascular Disease, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.

Introduction: Allisartan isoproxil is a novel angiotensin II type 1 receptor antagonist that has been confirmed to lower blood pressure and protect target organs effectively. However, its role in improving endothelial function and vascular damage has not been investigated yet.

Methods: Patients with initially diagnosed mild essential hypertension (BP ranging from 140/90 to 159/99 mmHg) with age from 25-75 years were randomly assigned 1:1 to either the allisartan group (allisartan 240 mg/day and lifestyle modification) or the lifestyle modification group and were followed up for 30 days. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01413-yDOI Listing

Correction to: Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study.

Adv Ther 2020 Jun 21. Epub 2020 Jun 21.

Department of Ophthalmology, Semmelweis University, Budapest, Hungary.

In the original article, the The VISIONARY Study Group Principal Investigator Jose Javier Garcia-Medina. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01407-wDOI Listing

Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran.

Adv Ther 2020 Jun 20. Epub 2020 Jun 20.

Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.

Introduction: Dabigatran is a direct oral anticoagulant (DOAC) used for the treatment of several thrombotic conditions. To date, very few pharmacogenetic studies on dabigatran were published. We aimed to investigate the influence of 59 polymorphisms in 15 genes (including CES1, UGT and CYP that encode enzymes and ABCB1 and SLC that encode transporters), concomitant treatment with pantoprazole and demographic characteristics (including sex or race) on dabigatran pharmacokinetics and safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01414-xDOI Listing

Estimating the Epidemiological and Economic Impact of Implementing Preoperative Anaemia Measures in the German Healthcare System: The Health Economic Footprint of Patient Blood Management.

Adv Ther 2020 Jun 19. Epub 2020 Jun 19.

Vifor Pharma, Health Economics & Outcomes Research, Flughofstrasse 61, Zurich, Switzerland.

Introduction: This study aimed to quantify the potential epidemiological and health economic benefits of implementing preoperative anaemia measures (PAMs) in clinical practice in the German healthcare system.

Methods: An evidence-based health economic model was developed to assess the possible impact of implementing PAMs, the first pillar of patient blood management (PBM), in a German population. The analysis of two risk factors-iron-deficiency anaemia (IDA) and receipt of a red blood cell concentrate (RBC) transfusion during elective surgery-allowed the estimation of relative risks (RRs), average cost per patient, average length of hospital stay, and avoided hospital deaths after the implementation of PAMs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01372-4DOI Listing

Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Essential Hypertension (RESOLVE): A Large, Observational, Retrospective, Cohort Study.

Adv Ther 2020 Jun 18. Epub 2020 Jun 18.

Medical Affairs Department, Daiichi Sankyo Korea Co., Ltd., Seoul, Republic of Korea.

Background: The efficacy and safety of a single-pill combination (SPC) of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) have been established previously through multiple studies. However, the real-world data in Korean patients are still limited. This study evaluated the effectiveness and safety of SPC of OLM/AML/HCTZ in a real practice setting in Korean patients with essential hypertension. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01404-zDOI Listing

Correction to: Panel Discussion: Some Aspects of the Management of Patients with X-Linked Hypophosphataemic Rickets.

Adv Ther 2020 Jun 17. Epub 2020 Jun 17.

Departamento de Medicina, Universidad de Granada, UGC Endocrinología y Nutrición. Hospital Universitario San Cecilio, CIBERFES, Instituto de Salud Carlos III, Instituto de Investigación Biosanitaria de Granada, Granada, Spain.

In the original article, there is an error in age related reference. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01406-xDOI Listing

Correction to: Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.

Adv Ther 2020 Jul;37(7):3149

IQVIA, Falls Church, VA, USA.

In the original article, it has been noticed that the abbreviation ''CLL'' is incorrectly published throughout the paper as the abbreviation "CCL". The correct abbreviation is "CLL". Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01400-3DOI Listing

Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.

Adv Ther 2020 Jul 12;37(7):3392-3403. Epub 2020 Jun 12.

Division of Oncology, Department of Medicine, Seattle Cancer Care Alliance, Seattle, WA, USA.

Introduction: Currently available second-line (2L) therapies for advanced/metastatic esophageal squamous cell carcinoma (adv/met ESCC) include the taxanes paclitaxel and docetaxel. In clinical trials, such therapies have provided only modest improvements in survival. Few studies have assessed outcomes in routine clinical practice in the USA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01394-yDOI Listing

Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis.

Adv Ther 2020 Jul 10;37(7):3404-3416. Epub 2020 Jun 10.

Department of Hematology, Seoul St. Mary's Hospital, Seoul, Republic of Korea.

Introduction: The primary analysis of a global phase 3 study that evaluated the efficacy and safety of denosumab versus zoledronic acid for preventing skeletal-related events (SREs) in adults with newly diagnosed multiple myeloma (MM) indicated that denosumab was noninferior to zoledronic acid for time to first on-study SREs. Here we present a subgroup analysis to evaluate efficacy and safety in Asian patients.

Methods: Patients were randomized 1:1 to receive denosumab 120 mg subcutaneously or zoledronic acid intravenously 4 mg every 4 weeks in a double-blind, double-dummy fashion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01395-xDOI Listing
July 2020
2.438 Impact Factor

PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers.

Adv Ther 2020 Jul 10;37(7):3370-3391. Epub 2020 Jun 10.

Pfizer Inc, Lake Forest, IL, USA.

Introduction: PF-06881894 is a proposed biosimilar to pegfilgrastim (Neulasta). This study evaluated the pharmacodynamic/pharmacokinetic (PD/PK) equivalence, immunogenicity, and safety of PF-06881894 vs pegfilgrastim reference products (US- and EU-Neulasta) in healthy volunteers.

Methods: A phase 1, open-label, randomized, crossover study was conducted to assess the pharmacologic equivalence and safety of a single 6-mg dose of PF-06881894, pegfilgrastim-US, and pegfilgrastim-EU. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01387-xDOI Listing

A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?

Adv Ther 2020 Jul 10;37(7):3040-3058. Epub 2020 Jun 10.

Analysis Group, Inc., Boston, MA, USA.

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapies can be effective for diffuse large B-cell lymphoma (DLBCL), a cancer with limited treatment options and poor outcomes, particularly for patients with relapsed or refractory (r/r) disease. Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CAR T-cell therapies approved by regulatory bodies for certain patients with r/r DLBCL on the basis of demonstrated treatment effects in their pivotal single-arm trials, ZUMA-1 and JULIET, respectively. In the absence of head-to-head trials, the question of whether a valid indirect treatment comparison (ITC) between axi-cel and tisa-cel could be performed using existing evidence is of interest to patients, physicians, payers, and other stakeholders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01397-9DOI Listing

Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.

Adv Ther 2020 Jul 9;37(7):3348-3369. Epub 2020 Jun 9.

Creativ-Ceutical, Paris, France.

Introduction: Currently, 15-20% of individuals with coronary artery disease (chronic coronary syndrome [CCS]) or peripheral artery disease (PAD) receiving routine treatment experience cardiovascular events (CVEs) within 3-4 years. Using PICOSTEPS (Patients-Intervention-Comparators-Outcomes-Setting-Time-Effects-Perspective-Sensitivity analysis) reporting, we evaluated the cost-effectiveness of recently approved rivaroxaban 2.5 mg twice daily in combination with acetylsalicylic acid 100 mg daily (RIV + ASA) for the prevention of CVEs among Finns with CCS or symptomatic PAD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01398-8DOI Listing

Correction to: Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study.

Adv Ther 2020 Jul;37(7):3162

The Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaoning Province, China.

In the original article, t. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01401-2DOI Listing

Troponin Levels Relate to CRP Concentrations in Patients With NAFLD on Maintenance Haemodialysis: A Retrospective Study.

Adv Ther 2020 Jul 8;37(7):3337-3347. Epub 2020 Jun 8.

Department of Clinical Medicine and Surgery, "Federico II" University, Medical School, Naples, Italy.

Introduction: Several studies have shown that high sensitivity cardiac troponin (hs-cTnT) levels are elevated in patients suffering from end-stage renal disease (ESRD), even in the absence of clinical signs and instrumental features of symptomatic acute coronary syndrome (ACS). In patients undergoing haemodialysis because of ESRD, nephrologists bear witness to this increase, whose origin and clinical impact are not yet well defined.

Methods: By a retrospective study, we evaluated data from records of 70 patients with ESRD on haemodialysis, all of them with a history of NAFLD, not suffering for at least 3 months from symptomatic angina and without a history of ischemic heart disease in the same period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01385-zDOI Listing

Dysfunctional Coagulation in COVID-19: From Cell to Bedside.

Adv Ther 2020 07 5;37(7):3033-3039. Epub 2020 Jun 5.

Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, 277 Yanta West Road, Xi'an, 710061, China.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which can induce multisystem disease. Human angiotensin-converting enzyme 2 (ACE2) widely expressing in arterial and venous endothelial cells and arterial smooth muscle cells has been identified as a functional receptor for SARS-CoV-2. Dysfunction of ACE2 leads to abnormal activation of the renin-angiotensin system and a systemic endotheliitis that may relate to abnormal coagulation and sepsis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01399-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274265PMC

Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan.

Adv Ther 2020 Jul 4;37(7):3324-3336. Epub 2020 Jun 4.

Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.

Introduction: Persistence with antipsychotic treatment is critical in managing patients with schizophrenia. To evaluate whether aripiprazole long-acting injection (aripiprazole once-monthly, AOM) can contribute to longer treatment persistence compared with daily orally administered aripiprazole (OA) in real-world clinical settings in Japan, treatment persistence in patients with schizophrenia was compared between patients treated with AOM and those with OA, using a claims database compiled by JMDC Inc., Tokyo, Japan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01396-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314731PMC

Diagnosis and Management of Hypothyroidism in Gulf Cooperation Council (GCC) Countries.

Adv Ther 2020 Jul 1;37(7):3097-3111. Epub 2020 Jun 1.

Merck Serono Middle East FZ LLC, Dubai, United Arab Emirates.

Hypothyroidism is one of the most common chronic endocrine conditions. However, as symptoms of hypothyroidism are non-specific, up to 60% of those with thyroid dysfunction are unaware of their condition. Left untreated, hypothyroidism may contribute to other chronic health conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01382-2DOI Listing

Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review.

Adv Ther 2020 Jul 1;37(7):3112-3128. Epub 2020 Jun 1.

Coordinator of the International Head and Neck Scientific Group, Padua, Italy.

Introduction: Aggressive variants of papillary thyroid cancer (PTC) have been described with increasing frequency. These variants include diffuse sclerosing variant, tall cell variant, columnar cell variant, solid variant, and hobnail variant.

Methods: We have performed a review of the more aggressive variants of PTC with respect to main characteristics, histological and molecular features, and the consequences that the knowledge of these variants should have in the treatment of the patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01391-1DOI Listing

Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.

Adv Ther 2020 Jul 29;37(7):3311-3323. Epub 2020 May 29.

Department of Thoracic Oncology, National Cancer Center Hospital, 5 Chome-1-1 Tsukiji, Chūō City, Tokyo, 104-0045, Japan.

Introduction: The anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) alectinib was approved in Japan in 2014 for the treatment of ALK fusion gene-positive advanced non-small cell lung cancer (NSCLC). With the approvals of crizotinib in 2012 and ceritinib in 2017, Japan became the first country with multiple ALK TKIs available for first-line or later use in patients with ALK-positive advanced NSCLC. Here, we collected and evaluated real-world data on ALK TKI clinical usage patterns and sequencing in patients with ALK-positive NSCLC in Japan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01392-0DOI Listing
July 2020
2.438 Impact Factor

Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO and OTEMTO Studies.

Adv Ther 2020 May 27. Epub 2020 May 27.

Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA.

Introduction: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report recommends long-acting muscarinic antagonists (LAMA) or long-acting β-agonists (LABA) as first-line treatment for chronic obstructive pulmonary disease (COPD), but many patients remain symptomatic on monotherapy and escalation to dual-bronchodilator therapy may be warranted.

Methods: TONADO 1&2 and OTEMTO 1&2 assessed lung function and patient-reported outcomes in patients with moderate-to-severe (OTEMTO) or moderate-to-very-severe (TONADO) COPD. This pooled post hoc analysis included patients treated with LAMA monotherapy at baseline who were randomised to receive either 5 µg tiotropium (LAMA) or 5/5 µg tiotropium/olodaterol (LAMA/LABA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01373-3DOI Listing

Antimicrobial De-Escalation in the ICU: From Recommendations to Level of Evidence.

Adv Ther 2020 Jul 27;37(7):3083-3096. Epub 2020 May 27.

MEPHI, IHU Méditerranée Infection, Aix Marseille Université, Marseille, France.

Antimicrobial de-escalation (ADE) is a component of antimicrobial stewardship (AMS) aimed to reduce exposure to broad-spectrum antimicrobials. In the intensive care unit, ADE is a strong recommendation that is moderately applied in clinical practice. Following a systematic review of the literature, we assessed the studies identified on the topic which included one randomized controlled trial and 20 observational studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01390-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252418PMC

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a.

Adv Ther 2020 Jul 25;37(7):3299-3310. Epub 2020 May 25.

Baylor College of Medicine, Gastroenterology, Hepatology, and Nutrition, Texas Children's Liver Center, Houston, TX, USA.

Introduction: To assess the safety, efficacy, and pharmacokinetics of mini-tablet formulations of ombitasvir (OBV), paritaprevir (PTV), ritonavir, and dasabuvir (DSV) with or without ribavirin for 12 weeks in children infected with chronic hepatitis C virus (HCV) genotype (GT) 1.

Methods: This is an ongoing, open-label, Phase 2/3 study in children 3-11 years old infected with HCV GT1 who were HCV treatment-naïve and non-cirrhotic. Pediatric mini-tablet formulations of OBV, PTV, ritonavir, and DSV plus ribavirin oral solution were administered for 12 weeks based on body weight. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01389-9DOI Listing

Prevalence and Management Challenges in Central Post-Stroke Neuropathic Pain: A Systematic Review and Meta-analysis.

Adv Ther 2020 Jul 23;37(7):3278-3291. Epub 2020 May 23.

Medical School, University of Cyprus, Nicosia, Cyprus.

Introduction: Central post-stroke pain (CPSP) is defined as the neuropathic pain that arises either acutely or in the chronic phase of a cerebrovascular event and is a result of central lesions of the somatosensory tract. The aim of this systematic review and meta-analysis was to establish the prevalence of CPSP, to describe its characteristics, and to discuss the associated management challenges.

Methods: After a systematic Medline search, we identified 69 papers eligible to be included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01388-wDOI Listing

Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.

Adv Ther 2020 Jul 21;37(7):3292-3298. Epub 2020 May 21.

Decision Resources Group, Burlington, USA.

Introduction: Idiopathic pulmonary fibrosis (IPF) is the classic progressive fibrosing interstitial lung disease (ILD), but some patients with ILDs other than IPF also develop a progressive fibrosing phenotype (PF-ILD). Information on use and cost of healthcare resources in patients with PF-ILD is limited.

Methods: We used USA-based medical insurance claims (2014-2016) to assess use and cost of healthcare resources in PF-ILD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01380-4DOI Listing

Correction to: Panel Discussion: Some Aspects of the Management of Patients with X-Linked Hypophosphataemic Rickets.

Adv Ther 2020 Jul;37(7):3432

Departamento de Medicina, Universidad de Granada, UGC Endocrinología y Nutrición, Hospital Universitario San Cecilio, CIBERFES, Instituto de Salud Carlos III, Instituto de Investigación Biosanitaria de Granada, Granada, Spain.

In the original article, third author name has been published incorrectly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01370-6DOI Listing

Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.

Adv Ther 2020 Jul 23;37(7):3265-3277. Epub 2020 May 23.

Department of Pharmacy, Rocky Mountain Cancer Centers, Greenwood Village, CO, USA.

Purpose: To evaluate the impact on cost, time, resource use, and clinic workflow of converting the route of drug administration from a neurokinin-1 receptor antagonist (NK-1 RA) 30-min intravenous (IV) infusion to aprepitant IV, and more specifically to IV push, within a multicenter community oncology practice.

Methods: This was a retrospective, multicenter time, motion, and resource/cost evaluation study. Conversion to aprepitant IV was determined by calculating number of doses of aprepitant IV versus fosaprepitant administered in patients receiving moderately or highly emetogenic chemotherapy regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01377-zDOI Listing

The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach.

Adv Ther 2020 Jul 22;37(7):3246-3264. Epub 2020 May 22.

Boehringer Ingelheim, Amsterdam, The Netherlands.

Introduction: The term progressive fibrosing interstitial lung disease (ILD) describes patients with fibrotic ILDs who, irrespective of the aetiology of the disease, show a progressive course of their disease despite current available (and non-licensed) treatment. Besides in idiopathic pulmonary fibrosis, little is known about management and the burden of patients with fibrotic ILD, particularly those with a progressive behaviour.

Methods: Using the Delphi method, 40 European experts in ILD management delivered information on management of (progressive) fibrosing ILD and on the impact of the disease on patients' quality of life (QoL) and healthcare resource utilisation (HCRU). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01384-0DOI Listing

The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review.

Adv Ther 2020 Jul 22;37(7):3059-3082. Epub 2020 May 22.

Institut de Cancérologie de Strasbourg, Strasbourg, France.

Epigenetic processes are essential for normal development and the maintenance of tissue-specific gene expression in mammals. Changes in gene expression and malignant cellular transformation can result from disruption of epigenetic mechanisms, and global disruption in the epigenetic landscape is a key feature of cancer. The study of epigenetics in cancer has revealed that human cancer cells harbor both genetic alterations and epigenetic abnormalities that interplay at all stages of cancer development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01379-xDOI Listing
July 2020
2.438 Impact Factor

Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.

Adv Ther 2020 Jul 22;37(7):3417-3431. Epub 2020 May 22.

F. Hoffmann-La Roche AG, Global Product Development Medical Affairs, 4070, Basel, Switzerland.

Introduction: Etrolizumab is a next-generation anti-integrin with dual action that targets two pathways of inflammation in the gut. A robust phase 3 clinical program in ulcerative colitis (UC) and Crohn's disease is ongoing and will evaluate the efficacy and safety of etrolizumab in well-defined patient populations in rigorous trials that include direct head-to-head comparisons against approved anti-tumor necrosis factor alpha agents (anti-TNF). The etrolizumab phase 3 clinical program consists of six randomized controlled trials (RCTs; UC: HIBISCUS I and II, GARDENIA, LAUREL, HICKORY; Crohn's disease: BERGAMOT) and two open-label extension trials (OLEs; UC: COTTONWOOD; Crohn's disease: JUNIPER) evaluating patients with moderately to severely active UC or Crohn's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01366-2DOI Listing

Persistence of Inflammation After Uncomplicated Cataract Surgery: A 6-Month Laser Flare Photometry Analysis.

Adv Ther 2020 Jul 21;37(7):3223-3233. Epub 2020 May 21.

Ophthalmology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Purpose: To evaluate, by laser photometry, the persistency of anterior chamber flare after uneventful phacoemulsification in asymptomatic patients with no signs of inflammation on slit lamp examination.

Method: Seventy-five patients previously enrolled in a randomized clinical trial that evaluated inflammation after uneventful phacoemulsification in eyes treated with dexamethasone 0.1% ophthalmic suspension (group 1) or bromfenac 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01383-1DOI Listing

Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients.

Adv Ther 2020 Jul 21;37(7):3234-3245. Epub 2020 May 21.

Drug Development Research Laboratory, Maruho Co., Ltd., Kyoto, Japan.

Introduction: Amenamevir (ASP2151), a herpesvirus helicase-primase inhibitor, is currently used for the treatment of herpes zoster in Japan. Amenamevir is mainly metabolized in the liver, and urinary excretion of amenamevir is approximately 10% in healthy adults. The increase of systemic exposure in non-dialysis patients with severe renal impairment was much less than that associated with nucleoside antiviral agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01375-1DOI Listing

Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.

Adv Ther 2020 Jul 20;37(7):3163-3177. Epub 2020 May 20.

IBM Watson Health, Cambridge, MA, USA.

Objective: Disease-modifying therapies (DMTs) can reduce multiple sclerosis (MS) relapse rates; however, effectiveness of treatments may vary. It is important to understand real-world treatment patterns in the context of MS relapses. We describe MS relapses related to treatment patterns among patients who switch treatment after their first DMT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01367-1DOI Listing

Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.

Adv Ther 2020 Jul 20;37(7):3178-3184. Epub 2020 May 20.

S.C. Cardiologia, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Napoli, Italy.

Introduction: Cardiovascular toxicity of immunotherapy represents an underreported but potentially fatal side effect. A relatively high incidence of pericardial disease has been noticed in patients with non-small cell lung cancer (NSCLC).

Methods: We retrospectively analyzed a population of patients with advanced NSCLC receiving immune checkpoint inhibitors (ICIs) looking for the presence of pericardial effusion at baseline or during treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01386-yDOI Listing
July 2020
2.438 Impact Factor

Development and Validation of a Nomogram-Based Prognostic Evaluation Model for Sarcomatoid Hepatocellular Carcinoma.

Adv Ther 2020 Jul 20;37(7):3185-3205. Epub 2020 May 20.

Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Introduction: Sarcomatoid hepatocellular carcinoma (SHC) is a rare subtype of liver cancer with extremely poor prognosis. This study aimed to identify the prognostic factors and develop an exclusive and efficient nomogram to predict cancer-specific survival (CSS) for SHC.

Methods: The data on patients diagnosed with SHC from January 1973 to December 2015 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database, and these patients were included as the training cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01357-3DOI Listing